Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received

Affiliations

• ¹ Lowell E. Schnipper, Beth Israel Deaconess Medical Center, Harvard Medical School; Therese Mulvey and Jeffrey Peppercorn, Massachusetts General Hospital; Deborah Schrag, Dana-Farber Cancer Institute, Boston, MA; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh; Adam P. Dicker, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA; Dana S. Wollins and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Douglas W. Blayney, Stanford University Medical Center, Stanford; Patricia A. Ganz, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles; Peter P. Yu, Palo Alto Medical Foundation, Palo Alto, CA; J. Russell Hoverman, Texas Oncology, Dallas, TX; Robert Langdon, Nebraska Cancer Specialists; Julie M. Vose, University of Nebraska Medical Center, Omaha, NE; Gary H. Lyman, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Neal J. Meropol, University Hospitals Case Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center, and Case Western Reserve University, Cleveland, OH; Lee Newcomer, UnitedHealthcare, Minneapolis, MN; Blase Polite, University of Chicago Medicine, Chicago, IL; Derek Raghavan, Levine Cancer Institute, Charlotte, NC; Gregory Rossi, AstraZeneca, Macclesfield, United Kingdom; Leonard Saltz and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; and Thomas J. Smith, Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD. [email protected].
• ² Lowell E. Schnipper, Beth Israel Deaconess Medical Center, Harvard Medical School; Therese Mulvey and Jeffrey Peppercorn, Massachusetts General Hospital; Deborah Schrag, Dana-Farber Cancer Institute, Boston, MA; Nancy E. Davidson, University of Pittsburgh Cancer Institute and University of Pittsburgh Medical Center Cancer Center, Pittsburgh; Adam P. Dicker, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA; Dana S. Wollins and Richard L. Schilsky, American Society of Clinical Oncology, Alexandria, VA; Douglas W. Blayney, Stanford University Medical Center, Stanford; Patricia A. Ganz, Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles; Peter P. Yu, Palo Alto Medical Foundation, Palo Alto, CA; J. Russell Hoverman, Texas Oncology, Dallas, TX; Robert Langdon, Nebraska Cancer Specialists; Julie M. Vose, University of Nebraska Medical Center, Omaha, NE; Gary H. Lyman, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA; Neal J. Meropol, University Hospitals Case Medical Center Seidman Cancer Center, Case Comprehensive Cancer Center, and Case Western Reserve University, Cleveland, OH; Lee Newcomer, UnitedHealthcare, Minneapolis, MN; Blase Polite, University of Chicago Medicine, Chicago, IL; Derek Raghavan, Levine Cancer Institute, Charlotte, NC; Gregory Rossi, AstraZeneca, Macclesfield, United Kingdom; Leonard Saltz and Clifford A. Hudis, Memorial Sloan Kettering Cancer Center, New York, NY; and Thomas J. Smith, Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD.